1Park DI, Kang MS, Oh SJ, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer [J]. Int Colorectal Dis, 2007, 22(5): 491-497.
2Park DI, Yun JW, Park JH, et al. Her-2/neu amplification is an independent prognostic factor in gastric cancer [J]. Dig Dis Sci, 2006, 51(8): 1371-1379.
4Ming T, Ping L, Kristine S, et al. ErbB2 promotes Src synthesis and stability: Novel mechanisms of Src activation that confer breast cancer metastasis [J]. Cancer Res, 2005, 65(5) : 1858- 1867.
5Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer [J]. Clin Oncol, 2002,20(3): 719-726.
6Angelika B, Riemer, Markus K, et al. Generation of peptlde mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu [J]. Immunology, 2004, 173(1) : 394 - 401.
7Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxlcity against tumor targets [ J]. Nat Med, 2000, 6(4): 443-446.
8Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, pachtaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor recptor 2-positive operable breast cancer [J]. Chn Oncol, 2005, 23(16): 3676 - 3685.
9Romond EH, Perez EA, Bryant J, et al. Doxombicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer [J]. N Engl J Med, 2005, 555( 16): 1673- 1684.
10Jewell E, Secord AA, Brotherton T, et al. Use of trastuzumab in the treatment of metastatic endometrial cancer [J]. Int Gynecol Cancer, 2006, 16(3): 1370-1373.
同被引文献7
1Chand Y, Alam MA. Network biology approach for identifying key regula- tory genes by expression based study of breast cancer. Bioinformation, 2012,8:1132-1138.
2Scheurle D, Jahanzeb M, Aronsohn RS, et al. HER-2/neu expression in archival nonsmall cell lung carcinomas using FDAapproved Hereep test. Anticancer Res ,2000 ,20 :2091-2096.
3Seliger B, Rongcun Y, Atkins D, et al. HER-2/neu is expressed in human renal cell carcinoma at heterogene 2 a levels independently of tumor grad- ing and staging and can be recognized by HLA2A2.12 restricted cytotoxic T lymphocytes. Int J Cancer,2000,87:349-359.
4Roeh F, Jim6nez G, Casanova J. EGFR signalling inhibits Capicua de- pendent repression during specification of Drosophila wing veins. Devel- opment ,2002,129:993-1002.
5Sasaki T, Kitadai Y, Nakamura T, et al. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphoryl- ation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. Neoplasia,2007,9:1066-1077.
